Biogen also lowered its guidance for the full year, hurt by multiple Tecfidera generic entrants in the US.
AlphaGraphs
Biogen tops market estimates in Q3, lowers guidance
Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated. BIIB shares were trading flat immediately following the announcement. The […]
Biogen (NASDAQ: BIIB) reported third-quarter 2020 financial results before the opening bell on Wednesday. The biotechnology giant reported a 6% decline in Q3 revenues to $3.38 billion, beating the Wall Street consensus. Earnings of $8.84 per share were also stronger than what analysts had anticipated. BIIB shares were trading flat immediately following the announcement. The […]
ADVERTISEMENT